Commentary: what can epidemiology accomplish?
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to Sharon Schwartz.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
It is well known that the incidence odds ratio approximates the risk ratio when the disease of interest is rare, but increasingly overestimates the risk ratio as the disease becomes more common. However when assessing interaction, incidence odds ratios may not approximate risk ratios even when the disease is rare. We use the term "distributional interaction" to refer to interaction that appears when using incidence odds ratios that does not appear, or appears to a lesser degree, when using risk ratios. The interpretational problems that arise from this discrepancy can have important implications in epidemiologic research. Therefore, quantification of the relationship between the interaction odds ratio and the interaction risk ratio is warranted. In this paper, we provide a formula to quantify the differences between incidence odds ratios and risk ratios when they are used to estimate effect modification on a multiplicative scale. Using this formula, we examine the conditions under which these two estimates diverge. Furthermore, we expand this discussion to the implications of using incidence odds ratios to assess effect modification on an additive scale. Finally, we illustrate how distributional interaction arises and the problems that it causes using an example from the literature. Whenever the risk of the outcome variable is non-negligible, distributional interaction is possible. This is true even when the disease is rare (e.g., disease risk is less than 5%). Therefore, when assessing interaction on either an additive or multiplicative scale, caution should be taken in interpreting interaction estimates based on incidence odds ratios.
We critically reviewed the validity and interpretation of two analytical approaches that have been used in the molecular epidemiological literature to investigate the role of gene-environment (GxE) interactions in disease (D) causation. Several studies have attempted to use biomarkers of biologically effective dose (BBED) such as polycyclic aromatic hydrocarbon-DNA and alfatoxin-albumin adducts to assess possible GxE interactions. To truly determine whether BBED results from a GxE interaction that is causally implicated in disease development would require data on G, E, BBED, and D, and thus far, few studies have had data on each of these components. In the absence of data on an antecedent E, one approach has been to assess interactions between G and BBED on D and to interpret the results as providing information on the presence of GxE interactions. In the absence of data on G, another approach has been to control for E in analyses of BBED and D and to interpret nonnull risk estimates for BBED as reflecting the role of G. We show that neither approach is valid. Analyses of interactions between G and BBED cannot be used to draw conclusions about the presence or absence of GxE interactions. Similarly, analyses of BBED and D, controlling for E, do not provide insight into the role of G. We discuss how differences in the risk estimate for BBED, with and without control for E may be interpreted.
In this paper I argue that a fruitful discussion of the choice of outcomes in the sociological study of the social antecedents of mental health problems would benefit from a consideration of the goals that we are trying to achieve. The most clearly articulated goal is that of uncovering those aspects of society that produce harm. I examine the premises of the current conceptual framework--the stress paradigm--in light of its ability to fulfill this goal, and I discuss the implications for the types of outcome measures we use.